Hessemer V, Schmitt K
Universitäts-Augenklinik Giessen.
Ophthalmologe. 1995 Feb;92(1):31-4.
The anti-inflammatory effects of topical steroids and nonsteroidal anti-inflammatory drugs (NSAID) are claimed to be additive, according to fluorophotometric measurements. This finding was reevaluated using laser flare-cell photometry.
Thirty patients (61-79 years of age) without pre-existing deficiencies of the blood-aqueous barrier were investigated preoperatively as well as on day 1 and 3 after ECCE with IOL implantation. The laser flare-cell photometer (model FC-1000; Kowa Company) which was used for examination enables sensitive and exact in vivo determination of aqueous flare. The patients were randomly assigned to one of the following three treatment groups: group A, monotherapy with prednisolone 1% eyedrops (Inflanefran forte); group B, monotherapy with indomethacin 1% eyedrops (Chibro Amuno); group C, combination therapy with prednisolone 1% + indomethacin 1% eyedrops. One drop of either drug was administered five times per day to each patient, beginning immediately after completion of surgery. In addition, all patients received antibiotic therapy with gentamicin. Parabulbar or oral steroids were not administered.
Under monotherapy with prednisolone, the flare (photon counts/ms) on days 1 and 3 postoperatively averaged 30.9 and 27.8, respectively. Under indomethacin monotherapy, the flare values were similar (no significant differences). Under combination therapy with prednisolone+indomethacin, however, the flare values were significantly lower both on day 1 (24.2) and on day 3 (20.6).
Combination therapy with topical prednisolone+indomethacin thus seems superior to monotherapy with either of these agents. This confirms the previous fluorophotometric finding that the anti-inflammatory effects of topical steroids and NSAID are additive, a phenomenon attributable to different pharmacological sites of action.
根据荧光光度测量结果,局部用类固醇和非甾体抗炎药(NSAID)的抗炎作用据称具有相加性。本研究使用激光闪烁细胞光度法对这一发现进行了重新评估。
对30例(年龄61 - 79岁)术前及行白内障囊外摘除联合人工晶状体植入术后第1天和第3天的患者进行了研究,这些患者不存在血 - 房水屏障的既往缺陷。用于检查的激光闪烁细胞光度计(FC - 1000型号;兴和株式会社)能够在体内灵敏且准确地测定房水闪光。患者被随机分配到以下三个治疗组之一:A组,用1%泼尼松龙滴眼液(氟米龙 forte)单一疗法;B组,用1%吲哚美辛滴眼液(奇罗氨诺)单一疗法;C组,用1%泼尼松龙 + 1%吲哚美辛滴眼液联合疗法。术后立即开始,每位患者每天滴眼5次,每次1滴。此外,所有患者均接受庆大霉素抗生素治疗。未给予球周或口服类固醇。
在泼尼松龙单一疗法下,术后第1天和第3天的闪光(光子计数/毫秒)平均值分别为30.9和27.8。在吲哚美辛单一疗法下,闪光值相似(无显著差异)。然而,在泼尼松龙 + 吲哚美辛联合疗法下,第1天(24.2)和第3天(20.6)的闪光值均显著更低。
局部用泼尼松龙 + 吲哚美辛联合疗法似乎优于这两种药物中的任何一种单一疗法。这证实了先前荧光光度测量的发现,即局部用类固醇和NSAID的抗炎作用具有相加性,这一现象归因于不同的药理作用部位。